These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
193 related items for PubMed ID: 19648005
1. Identification of small molecule inhibitors of proline-rich tyrosine kinase 2 (Pyk2) with osteogenic activity in osteoblast cells. Allen JG, Lee MR, Han CY, Scherrer J, Flynn S, Boucher C, Zhao H, O'Connor AB, Roveto P, Bauer D, Graceffa R, Richards WG, Babij P. Bioorg Med Chem Lett; 2009 Sep 01; 19(17):4924-8. PubMed ID: 19648005 [Abstract] [Full Text] [Related]
2. Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formation. Walker DP, Bi FC, Kalgutkar AS, Bauman JN, Zhao SX, Soglia JR, Aspnes GE, Kung DW, Klug-McLeod J, Zawistoski MP, McGlynn MA, Oliver R, Dunn M, Li JC, Richter DT, Cooper BA, Kath JC, Hulford CA, Autry CL, Luzzio MJ, Ung EJ, Roberts WG, Bonnette PC, Buckbinder L, Mistry A, Griffor MC, Han S, Guzman-Perez A. Bioorg Med Chem Lett; 2008 Dec 01; 18(23):6071-7. PubMed ID: 18951788 [Abstract] [Full Text] [Related]
3. Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271. Roberts WG, Ung E, Whalen P, Cooper B, Hulford C, Autry C, Richter D, Emerson E, Lin J, Kath J, Coleman K, Yao L, Martinez-Alsina L, Lorenzen M, Berliner M, Luzzio M, Patel N, Schmitt E, LaGreca S, Jani J, Wessel M, Marr E, Griffor M, Vajdos F. Cancer Res; 2008 Mar 15; 68(6):1935-44. PubMed ID: 18339875 [Abstract] [Full Text] [Related]
7. Small molecules with potent osteogenic-inducing activity in osteoblast cells. Han CY, Wang Y, Yu L, Powers D, Xiong X, Yu V, Nguyen Y, Jean DJ, Babij P. Bioorg Med Chem Lett; 2009 Mar 01; 19(5):1442-5. PubMed ID: 19179072 [Abstract] [Full Text] [Related]
14. Induction of proline-rich tyrosine kinase2 (Pyk2) through C/EBPbeta is involved in PMA-induced monocyte differentiation. Park MH, Park SY, Kim Y. FEBS Lett; 2008 Feb 06; 582(3):415-22. PubMed ID: 18198130 [Abstract] [Full Text] [Related]
15. 6-amino-4-(pyrimidin-4-yl)pyridones: novel glycogen synthase kinase-3β inhibitors. Coffman K, Brodney M, Cook J, Lanyon L, Pandit J, Sakya S, Schachter J, Tseng-Lovering E, Wessel M. Bioorg Med Chem Lett; 2011 Mar 01; 21(5):1429-33. PubMed ID: 21295469 [Abstract] [Full Text] [Related]
16. 4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: potent and selective p70S6 kinase inhibitors. Bandarage U, Hare B, Parsons J, Pham L, Marhefka C, Bemis G, Tang Q, Moody CS, Rodems S, Shah S, Adams C, Bravo J, Charonnet E, Savic V, Come JH, Green J. Bioorg Med Chem Lett; 2009 Sep 01; 19(17):5191-4. PubMed ID: 19632115 [Abstract] [Full Text] [Related]
17. Benzothiophene inhibitors of MK2. Part 1: structure-activity relationships, assessments of selectivity and cellular potency. Anderson DR, Meyers MJ, Kurumbail RG, Caspers N, Poda GI, Long SA, Pierce BS, Mahoney MW, Mourey RJ. Bioorg Med Chem Lett; 2009 Aug 15; 19(16):4878-81. PubMed ID: 19616945 [Abstract] [Full Text] [Related]